149 related articles for article (PubMed ID: 21498929)
1. Determinants of an optimal response to pioglitazone in terms of HDL-cholesterol.
Kabeya Y; Tomita M; Asai Y; Katsuki T; Oikawa Y; Meguro S; Shimada A; Atsumi Y
Intern Med; 2011; 50(8):825-31. PubMed ID: 21498929
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone hydrochloride in combination with sulfonylurea therapy improves glycemic control in patients with type 2 diabetes mellitus: a randomized, placebo-controlled study.
Kipnes MS; Krosnick A; Rendell MS; Egan JW; Mathisen AL; Schneider RL
Am J Med; 2001 Jul; 111(1):10-7. PubMed ID: 11448655
[TBL] [Abstract][Full Text] [Related]
3. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Rodríguez A; Reviriego J; Polavieja P; Mesa J
Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
[TBL] [Abstract][Full Text] [Related]
4. Effects of Sitagliptin on Lipid Profile in Patients With Type 2 Diabetes Mellitus After 7 Years of Therapy.
Derosa G; Tritto I; Romano D; D'Angelo A; Catena G; Maffioli P
J Clin Pharmacol; 2019 Oct; 59(10):1391-1399. PubMed ID: 31131461
[TBL] [Abstract][Full Text] [Related]
5. Differential regulations of lipid profiles between Japanese responders and nonresponders treated with pioglitazone.
Kutoh E
Postgrad Med; 2011 Jan; 123(1):45-52. PubMed ID: 21293083
[TBL] [Abstract][Full Text] [Related]
6. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
[TBL] [Abstract][Full Text] [Related]
7. One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes.
Hanefeld M; Brunetti P; Schernthaner GH; Matthews DR; Charbonnel BH;
Diabetes Care; 2004 Jan; 27(1):141-7. PubMed ID: 14693980
[TBL] [Abstract][Full Text] [Related]
8. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes.
Lawrence JM; Reid J; Taylor GJ; Stirling C; Reckless JP
Diabetes Care; 2004 Jan; 27(1):41-6. PubMed ID: 14693964
[TBL] [Abstract][Full Text] [Related]
9. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with glimepiride: a twelve-month, multicenter, double-blind, randomized, controlled, parallel-group trial.
Derosa G; Cicero AF; Gaddi A; Ragonesi PD; Fogari E; Bertone G; Ciccarelli L; Piccinni MN
Clin Ther; 2004 May; 26(5):744-54. PubMed ID: 15220018
[TBL] [Abstract][Full Text] [Related]
10. Lipid response to pioglitazone in diabetic patients: clinical observations from a retrospective chart review.
King AB; Armstrong DU
Diabetes Technol Ther; 2002; 4(2):145-51. PubMed ID: 12079617
[TBL] [Abstract][Full Text] [Related]
11. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
[TBL] [Abstract][Full Text] [Related]
12. Metformin-pioglitazone and metformin-rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndrome.
Derosa G; D'Angelo A; Ragonesi PD; Ciccarelli L; Piccinni MN; Pricolo F; Salvadeo SA; Montagna L; Gravina A; Ferrari I; Paniga S; Cicero AF
J Clin Pharm Ther; 2006 Aug; 31(4):375-83. PubMed ID: 16882108
[TBL] [Abstract][Full Text] [Related]
13. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
Betteridge DJ; Vergès B
Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
[TBL] [Abstract][Full Text] [Related]
14. Effect of pioglitazone and acarbose on endothelial inflammation biomarkers during oral glucose tolerance test in diabetic patients treated with sulphonylureas and metformin.
Derosa G; Mereu R; D'Angelo A; Salvadeo SA; Ferrari I; Fogari E; Gravina A; Palumbo I; Maffioli P; Randazzo S; Cicero AF
J Clin Pharm Ther; 2010 Oct; 35(5):565-79. PubMed ID: 20831680
[TBL] [Abstract][Full Text] [Related]
15. Addition of pioglitazone or bedtime insulin to maximal doses of sulfonylurea and metformin in type 2 diabetes patients with poor glucose control: a prospective, randomized trial.
Aljabri K; Kozak SE; Thompson DM
Am J Med; 2004 Feb; 116(4):230-5. PubMed ID: 14969650
[TBL] [Abstract][Full Text] [Related]
16. Comparing the effects of insulin glargine and thiazolidinediones on plasma lipids in type 2 diabetes: a patient-level pooled analysis.
Chaudhuri A; Rosenstock J; DiGenio A; Meneghini L; Hollander P; McGill JB; Dandona P; Ilgenfritz J; Riddle M
Diabetes Metab Res Rev; 2012 Mar; 28(3):258-67. PubMed ID: 22081557
[TBL] [Abstract][Full Text] [Related]
17. Effects of 1 year of treatment with pioglitazone or rosiglitazone added to glimepiride on lipoprotein (a) and homocysteine concentrations in patients with type 2 diabetes mellitus and metabolic syndrome: a multicenter, randomized, double-blind, controlled clinical trial.
Derosa G; Cicero AF; D'Angelo A; Gaddi A; Ciccarelli L; Piccinni MN; Salvadeo SA; Pricolo F; Ferrari I; Gravina A; Ragonesi PD
Clin Ther; 2006 May; 28(5):679-88. PubMed ID: 16861090
[TBL] [Abstract][Full Text] [Related]
18. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
Göke B;
Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
[TBL] [Abstract][Full Text] [Related]
19. Triple therapy with glimepiride in patients with type 2 diabetes mellitus inadequately controlled by metformin and a thiazolidinedione: results of a 30-week, randomized, double-blind, placebo-controlled, parallel-group study.
Roberts VL; Stewart J; Issa M; Lake B; Melis R
Clin Ther; 2005 Oct; 27(10):1535-47. PubMed ID: 16330290
[TBL] [Abstract][Full Text] [Related]
20. Differences in lipid profiles of patients given rosiglitazone followed by pioglitazone.
LaCivita KA; Villarreal G
Curr Med Res Opin; 2002; 18(6):363-70. PubMed ID: 12442884
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
